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Abstract
The cell-biological program termed the epithelial-mesenchymal transition (EMT) confers on 
cancer cells mesenchymal traits and an ability to enter the cancer stem cell (CSC) state. However, 
the interactions between CSCs and their surrounding microenvironment are poorly understood. 
Here we show that tumor-associated monocytes and macrophages (TAMs) create a CSC-niche via 
juxtacrine signaling with CSCs. We performed quantitative proteomic profiling and found that the 
EMT program upregulates the expression of CD90/Thy1 and EphA4, which mediate the physical 
interactions of CSCs with TAMs by directly binding with their respective counter-receptors on 
these cells. In response, the EphA4 receptor on the carcinoma cells activates Src and NF-κB, the 
latter results in the secretion of a variety of cytokines by the CSCs; these cytokines serve to sustain 
the stem-cell state. Indeed, admixed macrophages enhance the CSC activities of carcinoma cells. 
These findings underscore the significance of TAMs as important components of the CSC niche.
Despite improvements in diagnosis and treatment, breast cancer-associated mortality 
remains high due to clinical relapse associated with metastasis to distant organs. During 
primary tumor progression, breast carcinoma cells may pass through an EMT, thereby 
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acquiring traits associated with high-grade malignancy, including motility, invasiveness, and 
an increased resistance to apoptosis1, 2. Furthermore, passage of both normal and neoplastic 
mammary epithelial cells through an EMT confers on the cells many of the properties 
associated with normal mammary stem cells (MaSCs) and cancer stem cells (CSCs) 
respectively3–5. Importantly, carcinoma cells that have passed through an EMT exhibit 
heightened resistance to conventional chemotherapeutic agents and hence may regenerate 
tumor growth after initial drug treatment is halted6–8.
Various types of stromal cells have been found to influence the CSC state through paracrine 
signaling. As an example, mesenchymal stem cells contribute to the formation of CSCs by 
secreting prostaglandin E2 (PGE2), IL-6, IL-8 and Gro-α, which help to trigger activation of 
the previously latent EMT program in nearby carcinoma cells9. Periostin (POSTN) released 
by lung stromal fibroblasts fosters creation of a metastatic niche for breast cancer CSCs10. 
Some have speculated that a physical CSC-niche maintained by both paracrine and 
juxtacrine signaling exists in colon cancers similar to the normal colon stem cell niche 
supported by myofibroblasts11. Nevertheless, a juxtacrine-mediated CSC niche that 
maintains these cells in their stem-cell state has not been described.
Tumor-associated monocytes and derived macrophages (TAMs) have been shown to be 
involved in many aspects of tumor initiation and progression12, 13. These observations have 
not, however, shed light on how CSCs interact with TAMs in a manner different from non-
CSCs, and whether heterotypic interactions contribute to the formation and maintenance of 
the stem-cell niche.
Some have reported that normal MaSC function requires the continuing presence of 
macrophage-derived factors14, but the nature of these factors has not been explored. 
Moreover, it remains unclear whether the interactions between macrophages and normal 
MaSCs are relevant to carcinoma pathogenesis. In the present study, we describe a key 
mechanism by which already-formed mammary CSCs interact with niche-forming TAMs in 
a contact-dependent manner in order to maintain their residence in the mesenchymal/stem-
like state.
RESULTS
Quantitative proteomic profiling of cell-surface proteins
We and others have found extensive similarities between the stem-cell program of normal 
MaSCs and that of mammary CSCs3–5. To identify cell-surface proteins that enable normal 
and neoplastic mammary stem cells (SCs) to interact with nearby stromal cells, we 
performed quantitative proteomic profiling of membrane-associated proteins before and 
after immortalized human mammary epithelial cells (HMLE)15 were forced experimentally 
to undergo an EMT (and thereby acquire mesenchymal and SC traits). We employed stable 
isotope labeling by amino acids in cell culture (SILAC)16 followed by membrane-associated 
protein fractionation and mass spectrometry analysis (MS; Supplementary Fig. 1).
Plasma membrane- and extracellular matrix- associated proteins were represented by the 
most abundant peptides detected by MS (Supplementary Table 1). 2,607 proteins were 
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reproducibly identified with at least two peptide SILAC ratios measured in each replicate, 
with 460 proteins found to be either upregulated (277) or downregulated (183) significantly 
(P<0.05) in the EMT/stem-like cells after applying a moderated T-test17. Several known 
EMT marker proteins E-cadherin (CDH1), N-cadherin (CDH2), vimentin (VIM) and 
fibronectin (FN1) showed significant expression level changes in the expected directions, 
confirming the specificity of the proteomic profiling (Fig. 1a).
We focused subsequent analyses on the CD90/Thy1 protein, which was among the most 
strongly upregulated plasma membrane proteins (12.4 fold) following passage through an 
EMT. CD90 is a GPI-anchored glycoprotein and has been shown to interact with integrins 
displayed by adjacent cells18, 19. Its mRNA was also substantially upregulated during the 
EMT programs induced in HMLE cells by expression of the Twist, Snail, Slug or Zeb1 
EMT-TFs (Supplementary Fig. 2a).
Presence of stem-like cells in the CD90hi cell population
Because human mammary epithelial cells that have undergone an EMT can acquire stem-
like properties4, we postulated that CD90 expression was upregulated in MaSCs and breast 
CSCs. We analyzed the gene-expression data from two published reports and found a 
significant enrichment of CD90 expression in freshly isolated human mammary SC and 
CSC fractions in primary patient tissues across multiple specimens20, 21 (Supplementary Fig. 
2b,c).
We then examined the cell-surface antigen profile of HMLE-derived cells using anti-CD90 
and -CD24 antibodies. CD24 has been found to be mostly expressed in differentiated 
mammary epithelial cells21. Flow cytometry analysis revealed that 99% of HMLE-Twist 
cells and 18% of HMLE-Snail cells were CD90hiCD24−, whereas the HMLE-vector control 
cells only contained 0.1% cells in the same compartment (Fig. 1b), indicating that forced 
expression of either the Twist or Snail EMT-TFs led to substantial increases in 
CD90hiCD24− cells. The CD90hiCD24− cells from the three cell lines formed 
mammospheres22 with far higher efficiency than cell populations with lower CD90 
expression (Fig. 1c,d), providing further support for the association of CD90 expression with 
the MaSC state.
We subsequently undertook to measure the association of tumor-initiating ability with the 
CD90hiCD24− state in HMLE cells that had been transformed with the H-RasV12 oncogene 
(HMLER); this ability represents the operational definition of CSCs. Sorted HMLER cells 
were implanted orthotopically at limiting dilutions into NOD-SCID mice. The 
CD90hiCD24− HMLER cells initiated tumors at a 60-fold higher efficiently than the bulk 
HMLER cells and the tumors were more invasive and metastatic; the CD90lo populations 
rarely formed tumors (Fig. 2a–d). Similar results were observed when the sorted cell 
populations were implanted orthotopically into Nude mice (Supplementary Fig. 2d). CD90hi 
cells from the MB-MDA-435 human breast cancer cell line also formed larger and more 
aggressive tumors when compared to CD90lo cell populations (Supplementary Fig. 2e–g). 
Consistently, the expression level of CD90 is negatively correlated with patient survival, 
especially in ER− breast cancer (Fig. 2e,f). Taken together, these data demonstrated that the 
CD90 marker served to enrich for CSCs in carcinoma cells of mammary origin.
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Physical interaction between CD90hi CSC and TAMs
Reduced CD90 expression by shRNA knockdown resulted in delayed tumor onset and 
decreased tumor size (Fig. 2g) by the HMLER90hi cells, suggesting that CD90 has a 
functional role in tumor growth. CD90 has been shown to be expressed on activated 
endothelial cells, where it mediates the adhesion of monocytes via its counter-receptor 
MAC1 (integrin alphaM/betaV)19. We speculated that CD90 also serves as a physical 
anchor used by carcinoma stem cells to tether monocytes and derived macrophages. To test 
this notion in cell culture, we employed a human monocytic cell line THP123. GFP-
expressing HMLE-Ras cells were sorted into CD90hiCD24− (HMLER90hi) and 
CD90loCD24+ (HMLER90lo) populations (Supplementary Fig. 2h) and expanded in 
monolayer culture. RFP-expressing THP1 monocytes, normally propagated in suspension, 
were then added above the cell monolayers. We found that the RFP+ monocytes adhered in 
large numbers to the GFP+ monolayer of HMLER90hi cells, but rarely stay attached to the 
HMLER90lo cells (a 22-fold difference; Fig. 3a,b). ShRNA-mediated knockdown of CD90 
in HMLER90hi cells reduced the adherent monocytes by 3-fold, confirming the requirement 
of CD90 expression on the surface of the stem-like cells for efficient physical interaction 
with the monocytes (Fig. 3a, b middle panels).
Association of TAMs with CD90hi carcinoma cells in living tissues
In the xenograft tumors formed by HMLER90hi cells, CD90 expression was most prominent 
at the outer edge of tumor sections, where a high density of infiltrating tumor-associated 
macrophages (TAMs) was observed intermingled with CD90hi cancer cells (Fig. 3c,d), 
suggesting that CD90-mediated adhesion of TAMs to CSCs also occurs in vivo.
CD90 expression has been detected in primary human breast carcinomas on invading single 
cells or cell clusters24; in metastases the CD44+CD90+ subpopulation represents a major 
phenotype25. While TAM density in primary breast cancer has been correlated with poor 
prognosis26–28, a CSC-niche involving TAMs has not been demonstrated microscopically in 
patient tumor tissues. We undertook to verify direct contact between TAMs and CD90hi 
CSCs in patient breast cancer tissue by immunofluorescence analyses with anti-CD90 and -
CD68 (a cell-surface protein expressed largely by macrophages) antibodies. Juxtaposition of 
CD68+ TAMs with single-invading CD90hi CSCs was readily detected at the tumor-stroma 
interface (Fig. 3e; Supplementary Fig. 3a). Indeed, 24–51% of observed CD90hi cancer cells 
showed the presence of TAMs in close contact; in contrast very few (0 to 5%) CD90− 
cytokeratin+ (CTK+) cells were localized adjacent to TAMs (Fig. 3f,g; Supplementary Fig. 
3b). This direct visualization of the CSC-TAM juxtaposition in patient samples provided 
further support for the notion that CSCs and TAMs engage in direct contact in human breast 
tumors, where the latter cells help to form a niche for the CSCs.
We then expanded our analysis to include 25 core biopsy samples from patient tissues with 
invasive ductal carcinoma obtained during initial diagnostic core biopsies. The majority of 
CD90+ carcinoma cells showed reduced levels of cytokeratin expression, consistent with 
their passage through an EMT (Supplementary Fig. 3c). The number of CD68+ TAMs per 
microscopic field correlated with number of CD90+CTK− CSCs (r=0.44, P=0.002) but not 
with CD90−CTK+ non-CSCs (r=−0.12, P=0.60; Fig. 3h). This indicated that TAMs often 
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infiltrate CD90+ CSC-rich areas, allowing the juxtacrine signaling to occur. Accordingly, we 
could observe intermingling of CD68+ TAMs with CD90+ CSCs, but the macrophages 
rarely infiltrated into islands of CD90−CTK+ non-CSCs (Fig. 3i). Finally, consistent with 
this, analysis of the TCGA invasive breast carcinoma dataset revealed that CD90 expression 
in breast tumors positively correlated with CD68 expression (Supplementary Fig. 3e).
Monocytes/macrophages facilitate tumor outgrowth by the CSCs
Monocytes and macrophages in tumors have great functional plasticity12, 29. To test whether 
the CSC-TAM interaction that we observed is important to tumor formation, we depleted 
endogenous macrophages in the mammary fat pads at the time of implantation by co-
injecting the HMLER90hi cells with clodronate liposomes14. Nude mice were used in this 
and subsequent experiments instead of NOD-SCID hosts because of the documented defect 
in macrophage activation in the latter. Strikingly, tumor initiation was almost completely 
blocked by macrophage depletion, suggesting that endogenous macrophages in the tumor 
microenvironment are critical for the survival and proliferation of implanted CSCs (Fig. 4a). 
To examine the opposite effect, we co-injected HMLER90hi cells with either primary 
human monocytes or mouse TAMs isolated from HMLER90hi xenografts (Supplementary 
Fig. 4a). The admixture of either human monocytes or mouse TAMs resulted in higher 
tumor incidence and size, indicating that they promoted tumor outgrowth by CSCs (Fig. 4b).
The TAMs within tumors arising from CSCs showed low expression of Nos2 (M1 
polarization), and high expression of Arg1, MRC1, FIZZ1 and VEGF (M2 polarization30), 
which resembled the expression patterns of tumor-promoting TAMs31 isolated from 
mammary tumors in the MMTV-PyMT mice (Supplementary Fig. 4b). Moreover, when 
analyzing the CD68+ TAMs from the patient samples described above, we found that these 
cells were predominantly CD163+HLADR−/dim (Supplementary Fig. 4c), indicative of an 
M2, tumor-promoting phenotype32.
Various types of tumor-infiltrating immune cells, including lymphocytes, have been shown 
to modulate the function of TAMs33. Therefore we examined the effect of TAMs on CSC-
activities in immunocompetent mice. The MMTV-PyMT mice are known to develop 
mammary tumors that harbor CD90+ CSCs, which efficiently metastasize to the lungs when 
injected intravenously10. We sorted freshly-isolated mouse mammary carcinoma cells based 
on CD90 expression from the MMTV-PyMT-driven metastatic tumors and then injected the 
resulting CD90+ and CD90− populations, with or without TAMs, orthotopically into wild-
type syngeneic hosts. All groups developed tumors of similar weight (Supplementary Fig. 
4d); lymphocyte infiltration was readily detected within the tumors, resembling 
spontaneously arising MMTV-PyMT tumors (Supplementary Fig. 4e,f). However, tumors 
that arose from CD90− non-CSCs (with or without co-injected TAMs) were largely necrotic 
and contained cysts filled with fluid (Supplementary Fig. 4g,h), with low numbers of 
proliferating cells (Supplementary Fig. 4i,j) and no metastasis in the lungs (Fig. 4c,d). 
CD90+ CSCs injected on their own resulted in tumors with less necrosis and more 
proliferating cells but yielded very few lung metastases. In contrast, the CD90+ CSCs with 
co-injected TAMs resulted in tumors that contained little necrosis, were more proliferative, 
and metastasized to lung with a 22-fold higher efficiency than CD90+ CSCs injected alone. 
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These data supported the notion that the co-injected macrophages promoted more robust 
primary tumor growth and enhanced the metastatic CSC-activity of the CD90+ carcinoma 
cells in the context of an intact immune system.
We noted that both the CD90+ and CD90− MMTV-PyMT carcinoma cells initiated primary 
tumors efficiently. This is likely due to the fact that the tumor cells were isolated from 
spontaneously arising MMTV-PyMT tumors at the stage of metastatic dissemination, when 
most of the carcinoma cells had evolved to be rapidly proliferating following weeks of 
robust tumor growth.
Effects of admixed macrophages on tumor initiation
We reasoned that the direct contact of macrophages with the CSCs might allow the TAMs to 
provide signals important for the maintenance of their CSC state. To determine whether 
TAMs enhance tumor initiation rates and thus enrich for CSCs we performed tumor 
xenograft experiments by implanting the carcinoma cells in limiting dilutions. Co-injecting 
macrophages with the CD90hi CSCs resulted in earlier tumor onset (Fig. 4e,f), higher tumor 
incidence and burden compared to CSCs injected alone (Fig. 4g); in contrast, CD90lo non-
CSCs did not initiate tumors either with or without admixed TAMs (Fig. 4h).
To measure more precisely the frequency of CSCs from the tumors with admixed TAMs, we 
injected CSCs in the presence or absence of TAMs into mouse mammary fat pads and 
harvested the tumors three weeks later when they were no larger than 0.2 gram 
(Supplementary Fig. 4k). The cancer cells from the TAMs+CSCs group formed more 
tumorspheres and initiated tumors with a 17-fold higher efficiency in a secondary 
transplantation experiment than those from the CSCs-only injected tumors (Fig. 4i,j). Taken 
together, these data confirmed directly the ability of TAMs to boost the representation of 
CSCs in these carcinoma cell populations, ostensibly by enabling CSCs to maintain their 
residence in the stem cell state.
Monocytes/macrophages-stimulated cytokine production in the stem-like cells
We then sought to dissect the molecular mechanism for the interaction between CSCs and 
monocytes/macrophages. Because cytokines are known to mediate the interactions between 
cancer cells and TAMs29, we measured the expression of various cytokine mRNAs in both 
HMLER90hi cells and THP1 monocytes that had been separated by FACS (fluorescence-
activated cell sorting) after 3 hours of coculture (Supplementary Fig. 5a). Widespread 
changes in cytokine expression were already apparent in both cell populations within this 
time period (Supplementary Tables 2,3). Strikingly, we observed rapid and robust induction 
of mRNAs encoding IL-6, IL-8 and GM-CSF in the HMLER90hi cells, whose levels far 
exceeded the cytokines produced by the cocultured monocytes.
The mRNA levels of IL-6, IL-8 and GM-CSF rose abruptly upon monocyte coculture and 
persisted for at least 6 hrs (Fig. 5a). HMLER90lo cells, used as controls, only showed a 
modest and transient increase in these cytokines in response to monocyte coculture. 
Importantly, the induction of these cytokines in the HMLER90hi cells was completely 
blocked when they were separated from the monocytes by a cell-impermeable insert, 
indicating that the observed signaling between the two cell types required direct cell-cell 
Lu et al. Page 6
Nat Cell Biol. Author manuscript; available in PMC 2015 January 16.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
contact, i.e., juxtracrine signaling. Virtually no cytokines were detected in the conditioned 
medium by ELISA from mock-treated HMLER90hi cells in contrast with the robust 
increases of cytokine levels after 4 hrs of coculture (Fig. 5b); membrane-separated indirect 
cocultures yielded only marginal if any increases in the three cytokines. Knockdown of 
CD90 by shRNA resulted in 2- to 3-fold reduction in cytokine mRNA induction in the 
HMLER90hi cells (Fig. 5c), likely due to the reduced number of monocytes adhering to 
these cells.
We also noted that the induction of IL-6, IL-8 and GM-CSF in the stem-like cells did not 
require the actions of H-RasV12, because the CD90hiCD24− cells from the non-transformed 
HMLE-Twist and HMLE-Slug stem-like cells also responded to monocyte coculture by 
producing these cytokines, whereas the parental epithelial HMLE cells, used here as 
controls, showed only a marginal upregulation of the cytokines (Fig. 5c). In addition, 
cytokine induction in the CD90hi cells was also observed when primary mouse macrophages 
or primary human monocytes were used instead of THP1 monocytes (Fig. 5d,e), which 
indicated that the above observations applied to a variety of monocytes/macrophages, and 
that the signaling between mouse macrophages and the human HMLE-derived 
CD90hiCD24− cells was not compromised by inter-species signaling incompatibilities.
IL-6 and IL-8 have been shown to induce and maintain the CSC-state in autocrine and 
paracrine fashions9, 34, 35. In HMLER90hi cells, individual knockdown of IL-6 or IL-8 led 
to cessation of cell proliferation in culture, whereas the proliferation of epithelial HMLE-
Ras cells was unaffected by the knockdowns (Supplementary Fig. 5b,c). In addition, IL-8 
overexpression or treatment with recombinant IL-6 and/or IL-8 resulted in more efficient 
tumorsphere formation by the HMLER90hi cells, indicating that IL-6 and IL-8 can indeed 
act on the HMLER90hi cells to promote the expansion of CSCs (Supplementary Fig. 5d–f). 
GM-CSF is known to promote the differentiation of TAMs into tumor-supporting 
phenotypes12, 33, and may act in a paracrine fashion to perpetuate the CSC-TAM interaction. 
The three cytokines therefore may further reinforce and sustain the stem cell-state of the 
HMLER90hi CSCs.
Role of EphA4 in mediating signaling activation in the stem-like cells
We undertook to determine the molecular mechanisms that were responsible for the marked 
induction of cytokines following exposure of normal and neoplastic MaSCs to monocytes. 
CD90 lacks an intracellular domain and hence is poorly equipped to transduce signals across 
the plasma membrane18. As an alternative, we considered the well-documented CSF1-EGF 
paracrine loop between TAMs and breast cancer cells31, 36; however, the expression of 
EGFR is strongly downregulated during passage through an EMT6, 37, 38, rendering it 
unlikely to mediate the response of CSCs to TAMs.
We therefore searched for other cell-surface receptor candidates that could mediate the 
juxtacrine signaling from our proteomics analysis. Three receptor tyrosine kinases (RTKs) – 
ROR1 (a pseudokinase39), PDGFRβ and EphA4 – were strongly upregulated in the stem-
like cells (Fig. 1a, Supplementary Table 1, Supplementary Fig. 6a); among these, only 
EphA4 is known to mediate contact-dependent signaling following binding with plasma 
membrane-associated Ephrin ligands displayed on closely apposed cells40. We noted that 
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while peptides shared by several Eph RTKs showed little change in levels, MS analysis of 
the peptides unique to EphA4 revealed its upregulation by over 20-fold following passage 
through an EMT (see Methods).
We measured the activation of the RTKs upon contact with monocytes by immunoblotting 
after removal of monocytes following coculture (Supplementary Fig. 6b). Only EphA4 
showed a robust increase in activation in the stem-like HMLER90hi cells and HMLE-Twist 
cells upon direct monocyte coculture (Fig. 6a,b; Supplementary Fig. 6c).
A KYL peptide has been shown to specifically inhibit EphA4 activation41. Treatment of 
cocultures with the KYL peptide, but not the KYL-P7A control peptide41, blocked 90% of 
EphA4 phosphorylation in the HMLER90hi cells and significantly reduced the secretion of 
the three cytokines (Fig. 6c,d). Consistently, shRNA knockdown of EphA4 in the 
HMLER90hi cells hindered cytokine mRNA induction by monocytes (Supplementary Fig. 
6d,e). Taken together, these data demonstrated the involvement of EphA4 in monocyte-
stimulated cytokine production in EMT-induced stem-like cells. This was further supported 
by our observation that knockdown of EphA4 in the CSCs led to a 4-fold reduction in the 
size of resulting tumors (Fig. 6e).
Because EphA4 activation requires direct engagement of its ligand displayed on the surface 
of monocytes, it is likely that CD90 physically anchors the monocytes to the HMLER90hi 
cells, thereby providing the physical association that is essential for the Ephrin ligand-
receptor juxtacrine signaling. As expected, we observed that EphA4 phosphorylation in the 
CD90 knockdown cells was 40% lower than in the control cells when cocultured with 
monocytes (Supplementary Fig. 6f).
EphA4 receptor can promiscuously bind to both types of human Ephrin ligands, including 
five glycosylphosphatidylinositol (GPI)-linked ephrin-A ligands and three transmembrane 
ephrin-B ligands40. Pretreatment of the monocytes with recombinant PI-specific PLC prior 
to coculture resulted in decreased phosphorylation of the EphA4 receptor, indicating that the 
ephrin ligand(s) displayed by the monocytes belong to the GPI-anchored type A family 
(Supplementary Fig. 6g). Consistently, the EphA2 receptor, which only recognizes ephrin-A 
ligands was also activated in the CSCs upon coculture with monocytes. Given that EphA4 
can bind all five ephrin-A ligands, we did not pursue the precise identity of its cognate 
ephrin-A ligand(s) displayed by the monocytes/macrophages.
Intracellular signaling activated by the EphA4 receptor
In subsequent work, we sought to characterize the downstream signaling pathway of EphA4 
activation. EphA4 has been shown to bind and phosphorylate phospholipase Cγ1 (PLCγ1)42, 
which can activate a variety of protein kinase C (PKC) enzymes via its production of 
diacylglycerol (DAG)43. In addition, Src family kinases have also been shown to mediate 
downstream signaling of EphA444. Indeed, we observed strong phosphorylation of PLCγ1 
(Y783), PKCδ (Y311), and Src (Y416) in the CSC-like HMLER90hi cells in response to 
cocultured monocytes (Fig. 6a,b). Activation of these proteins was greatly reduced when 
treated with the KYL peptide (Fig. 6c)
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PKCδ is known to mediate degradation of IκB, allowing NF-κB to translocate into the 
nucleus45, which can then drive the transcription of various genes including IL-6, IL-8 and 
GM-CSF46–48. Indeed, knockdown of PLCγ1 and PKCδ in the HMLER90hi cells resulted in 
a 2–10 fold reduction in the induction of the three cytokine mRNAs (Fig. 6f,g). 
Consistently, phosphorylation of PLCγ1 could be readily detected in the tumor cells 
adjacent to TAMs in the HMLER90hi tumor xenografts (Fig. 6h).
NF-κB activation in the CSC-like HMLER90hi cells
We also undertook to examine in more detail the involvement of the PKCδ-stimulated NF-
κB signaling in the HMLER90hi cells. The expression of an NF-κB super-repressor (IκBα 
S32A/S36A)49 in the HMLER90hi cells blocked the cytokine mRNA induction in these 
cells following coculture with monocytes or macrophages (Fig. 7a,5d,5e). Secretion of the 
cytokines from the cocultured cells was also reduced by more than 10-fold when the NF-κB 
super-repressor was expressed in the HMLER90hi cells (Fig. 7b), which further 
demonstrated that the three cytokines were largely secreted by the HMLER90hi cells and 
not by the monocytes. Consistently, we observed a time-dependent nuclear accumulation of 
the NF-κB subunits p65 and, more strikingly, p50, in the CD90hi cells following coculture 
with the monocytes (Fig. 7c).
More importantly, human monocytes or TAMs failed to promote tumor-initiation or growth 
from the NF-κB super-repressor-expressing HMLER90hi cells, indicating that NF-κB 
activation and cytokine induction in the CSCs are functionally essential for the tumor-
promoting effects of the TAMs (Fig. 7d). In addition, the tumors from co-injected CSCs and 
TAMs had substantially fewer apoptotic cells, consistent with the well-known roles of NF-
κB pathway and Src in conferring resistance to apoptosis (Fig. 7e).
The Twist EMT-TF has been shown to mediate IL8 transcription in cooperation with RelA 
NF-κB subunit50. Indeed, we detected the association of the p50 NF-κB subunit with the 
endogenous Twist protein in the HMLER90hi cells by co-immunoprecipitation (Fig. 7f). 
Using chromatin immunoprecipitation (ChIP), we found that Twist was moderately enriched 
close to the transcription start-site of IL6, IL8 and CSF2 (encoding GM-SCF) in the absence 
of monocytes, whereas no binding of p50 was observed. Upon monocytes coculture, we 
detected significant increases in the binding of both Twist and p50 to the same promoter 
regions (Fig. 7g). Hence, it appears that when stimulated by monocytes/macrophages, the 
EphA4 protein on the HMLER90hi cells activates the NF-κB p50 subunit, which then enters 
the nucleus and cooperates with Twist to further increase its binding to the cytokine 
promoters, contributing to the robust cytokine induction in the stem-like cells (Fig. 7h).
DISCUSSION
The EMT program is an important component of carcinoma progression by conferring on 
the cancer cells invasiveness and by enriching for stem-cell properties2–4. Here, we have 
shown that EMT-induced stem-like HMECs (human mammary epithelial cells) interact with 
and respond to monocytes and macrophages far more robustly than do differentiated, non-
stem like HMECs. In the context of cancer, these cell-cell contact-dependent interactions 
provide evidence of a physical CSC-niche supported by the TAMs. Such direct contact 
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could be visualized in xenograft tumors as well as patient-derived breast tumor sections. 
Furthermore, we delineated the receptors and signaling pathways mediating such 
interactions in the CSCs, which were confirmed using tumor cell transplantation models. 
The observed responses of the CSCs appear to sustain their residence in the stem-cell state 
via self-reinforcing, positive-feedback loops (Supplementary Fig. 6h).
Intriguingly, co-injection of CD90+ MMTV-PyMT tumor cells with TAMs into the 
mammary fat pads of wildtype syngeneic mice resulted in more efficient lung metastases 
than CD90+ CSCs injected on their own. In addition to enhancing initial survival and 
proliferation of the CSCs, we suspect that the cohort of cytokines secreted in response to the 
TAM-CSC interaction facilitated the induction of tumor-supportive stroma, allowing tumor 
progression to metastatic carcinoma. In contrast, when CD90+ CSCs were injected alone 
into wildtype syngeneic hosts, in the absence of various tumor-promoting and immune-
suppressing cytokines produced by the interacting CSCs and TAMs, the subsequently 
recruited immune cells may have adopted tumor-suppressive phenotypes33. The effects of 
the immune cells on the CSC activities await further investigation.
During embryonic development, macrophages derive from the yolk sac and fetal liver prior 
to hematopoiesis, arising as the earliest cells of the hematopoietic lineage12. Among other 
functions, these tissue macrophages likely participate in embryonic organ development by 
providing effectors necessary for the formation and function of various tissue stem-cell 
niches. It has been reported that mouse mammary stem cell (MaSC) function requires the 
continuing presence of macrophages in the developing mammary gland14. This suggests that 
components of the heterotypic interactions between normal MaSCs and monocytes/
macrophages are recapitulated in the carcinoma SCs.
More broadly, the presently observed physical interactions between CSCs and TAMs may 
quite possibly operate in other carcinoma types. Increased expression of CD90 has been 
reported in CSCs of liver cancer, gastric cancer, colon cancer and glioma51–54. EphA4 
overexpression has been observed in gastric cancer55 and liver cancer metastasis56. 
Additional Ephrin receptor family members EphA2 and EphB2 have been shown to be 
upregulated in glioblastoma tumor-propagating cells and in colon CSCs11, 57. Accordingly, 
CD90 and Eph receptor(s) may well mediate interactions of CSCs and TAMs in a variety of 
carcinomas in order to maintain and reinforce the CSC-state. Indeed, such interactions may 
one day suggest potential targets for therapeutic attack on CSCs.
METHODS
Cell culture
HMLE, HMLE-Twist, HMLE-Snail, HMLE-Slug and HMLE-Ras cells were grown in 
MEGM medium (Lonza). MDA-MB-435 cells (ATCC) were grown in DMEM containing 
10% inactivated fetal bovine serum (IFS). THP1 cells (ATCC) were grown in RPMI1640 
containing 10% IFS with 5 mM β-mercaptoethanol. Cells were routinely tested for 
mycoplasma contamination.
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Coculture assays
The HMLE-derived cells were seeded into culture dishes at 30% confluency, and grown into 
a ~70% confluent monolayer 18 hr later. The THP1 monocytes were pelleted by 
centrifugation at 300×g, resuspended in the MEGM medium at 1 million cells/ml, and laid 
on top of the monolayer cells (cell number of monocytes: monolayer cells = 3:2). The non-
adherent monocytes were gently rinsed away after 1 hr by two washes of PBS, and the cells 
in the culture are replenished with fresh MEGM medium. Cells were trypsinized at indicated 
time points and resuspended in 2% IFS/PBS for FACS sorting. For conditioned medium 
collection, fresh MEGM medium was added to the coculture (without removing existing 
medium) after 1 hr, and the conditioned medium was collected after filtering through a 0.2 
micron Acrodisc syringe filter (Pall Life Science #PN4192). For the peptide inhibitor 
experiments, the monolayer HMLER90hi cells were treated with the indicated peptide or 
DMSO for 40 min before and during the monocytes coculture.
Fluorescence activated cell sorting (FACS) and flow cytometry
Cells were prepared according to standard protocols and suspended in 2% IFS/PBS. DAPI 
(Life Technologies) was used to exclude dead cells. Cells were sorted on BD FACSAria 
SORP and analyzed on BD LSRII, using BD FACSDiva Software (BD Biosciences). 
Antibodies used are anti-CD90-APC (BD Biosciences #559869), anti-CD24-PE (BD 
Biosciences #555428).
Mammosphere/tumorsphere culture
Mammosphere/tumorsphere culture was performed as previously described22. The number 
of cells seeded per well was labeled for each graph in figures. Sphere numbers were counted 
between days 8 to 12.
RNA preparation and qRT-PCR analysis
Total RNA was isolated using the RNeasy Plus Mini kit (Qiagen) and reverse transcription 
was performed with High Capacity RNA-to-cDNA Kit (Applied Biosystem), both according 
to the manufacturer’s protocol. A cDNA sample prepared from 1 μg total RNA was used for 
each PCR. The PCR reactions using SYBR Green Mix I (Roche Diagnostics), data 
collection, and data analysis were performed on the LightCycler® 480 System (Roche 
Diagnostics). The thermal cycling parameters for the PCR were as follows: 95°C for 5 min, 
followed by 45 cycles of 95°C for 10 sec, 49°C for 7 sec, and 72°C for 25 sec. The relative 
mRNA quantity was normalized against the relative quantity of GAPDH mRNA in the same 
sample. Primers used are indicated in Supplementary Table 4.
Enzyme-linked immune-sorbent assay (ELISA)
Concentrations of cytokines IL-6, IL-8 and GM-CSF in conditioned media were detected by 
ELISA kits from Ray Biotech (IL-6 and GM-CSF) and EBiosciences (IL-8) according to 
manufacturers’ protocols. The absorbance was measured on Multiskan EX (Thermo 
Electron Corporation).
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Cell proliferation assay
Cells were seeded in 96-well assay plates (Corning #3903) at 1000 cells/well, and the 
culture medium was replenished every 2 days. Cell proliferation was measured at indicated 
days after seeding with WST1 reagent (Roche 11644807001) according to manufacturer’s 
protocol.
Isolation of primary mouse macrophages and human monocytes
To isolate mouse intraperitoneal-exude macrophages (IPMCs), mice were injected with 2% 
v/v Bio-Gel P-100 (Bio-Rad #150-4174) intraperitoneally (1 ml/mouse). 3 days later, the 
mice were euthanized; RPMI media was injected intraperitoneally and then retrieved. The 
cells were then treated with Red Blood Cell Lysing Buffer (Sigma-Aldrich) and washed with 
PBS. The purity of the IPMCs was analyzed by flow cytometry after staining with anti-
CD11b-PE (BD Biosciences #557397), anti-Ly-6G-AlexaFlour700 (BD Biosciences 
#561236) and anti-F4/80-PE-Cy7 (EBiosciences 25-4801-82). Mouse tumor-associated 
macrophages (TAMs) were isolated from dissociated mouse tumors previously grown from 
the HMLE-Ras CD90hi cells. Human monocytes were isolated from human peripheral blood 
mononuclear cells from healthy donors. Mouse TAMs and human monocytes were purified 
by magnetic activated cell sorting (MACS) with anti-F4/80-PE-Cy7 followed by anti-PE 
microbeads (Miltenyi Biotec), and human CD14 microbeads (Miltenyi Biotec), according to 
manufacturer’s protocol. The purity of mouse TAMs were directly analyzed by flow 
cytometry after MACS. The purity of human monocytes was analyzed by flow cytometry 
after staining with anti-CD14-PE-Cy7 (25-0149-71), anti CD11b-APC (17-0118-71) 
antibodies (both from EBiosciences).
Creation of stable cell lines
GFP-labeled HMLE, HMLE-Twist and HMLE-Slug cell lines were made by retroviral 
transduction using the pWZL-blast-GFP expression vector59. HMLE-Ras cell line 
(HMLER) was made by retroviral transduction with the pMSCV-HRasV12-IRES-GFP 
expression vector60. The tdTomato fluorescent protein-labeled THP1 monocytes (THP1-
RFP) were made by lentiviral transduction using the pLV-tdTomato expression vector61. 
NF-κB super-repressor expressing HMLER90hi cells were made by retroviral transduction 
using the pBabe-puro-IκBα-S32A/S36A expression vector (Addgene plasmid 12332)62. 
Short hairpin RNAs (shRNA) targeting the mRNAs encoding CD90 (Thy1), EphA4, PLCγ1, 
PKCδ, IL-6, IL-8 and GM-CSF were expressed from pLKO.1-puro (Open Biosystems); the 
target sequences of these shRNA hairpins are indicated in Supplementary Table 5. All stable 
cell lines were generated via retroviral infection using HEK293T cells, as previously 
described63, and followed by selection with puromycin (2 ug/ml) or by cell sorting.
Western blotting
Phospho- and total- protein lysates were prepared with urea lysis buffer (9 M urea, 20 mM 
HEPES, pH 8.0), with freshly added phosphatase inhibitors (1 mM sodium orthovanadate, 5 
mM sodium pyrophosphate and 1 mM β-glycerol-phosphate). For the separation of 
monocytes from the monolayer HMLE-derived cells, phosphatase inhibitors (1 mM sodium 
orthovanadate, 5 mM sodium pyrophosphate) were added to the culture medium before 
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harvesting and the monocytes were repeatedly flushed off with the medium; the monolayer 
cells were rinsed with cold PBS and immediately lysed on the culture dish. The monocytes 
were then pelleted by centrifugation at 300xg for 5 min and then lysed. For Fig. 7c, nuclear 
and cytoplasmic extracts were prepared using NE-PER kit (Pierce). Concentrations were 
determined using the Dc protein assay (Bio-Rad). For Supplementary Fig. 6a, total protein 
was extracted with RIPA lysis buffer. Protein lysates were resolved on a 4%–12% Bis-Tris 
Gel, transferred to PVDF membranes, probed with primary antibodies overnight at 4°C and 
then with HRP-linked secondary antibodies (Cell Signaling Technology, CST) and 
visualized with ECL reagents (Thermo Scientific). The dilution, clone and catalog numbers 
of antibodies used are listed in Supplementary Table 6.
Co-immunoprecipitation (coIP) and Chromatin Immunoprecipitation (ChIP) Assay
CoIP of Twist and NF-κB p50 was performed using the HMLER90hi cells with endogenous 
high level of Twist. The monolayer cells were rinsed with cold PBS and lysed in the IP 
buffer (20 mM Tris, pH 7.5, 200 mM NaCl, 5 mM MgCl2, 0.1% NP40-substitute, 10% 
Glycerol, with 1 mM DTT, 0.5 mM PMSF and 1x protease inhibitor (Roche) fresh added 
before lysis). Cell lysates were incubated at 4°C with the anti-Twist antibody (Abcam # 
ab50887) or control IgG (CST, #5415) overnight (Supplementary Table 6). The protein-
antibody mixture was then precipitated with the protein G magnetic beads (Invitrogen) 
according to manufacturer’s protocols. NF-κB p50 was then detected with the anti-p105/p50 
antibody (CST, #3035) by western blot. ChIP assay was performed as previously described 
with the same antibodies64. The dilution, clone and catalog numbers of antibodies used are 
listed in Supplementary Table 6. The PCR primers used for confirming the protein bindings 
were: Promoter probe for IL6: TTCCAATCAGCCCCACCCG/
GCTGGCAGTTCCAGGGCTAAGG. Control probe for IL6: 
TCTGGAGACTGGAGGGACAACC/GGACGCAGGCACGGCTCTA. Promoter probe for 
IL8: CATCAGTTGCAAATCGTGGAAT/GAGTGCTCCGGTGGCTTTTTAT. Control 
probe for IL8: AAGAGCATGAAGCAACAGTGGC/
AATAGGAGGGCTTCAATAGAGG. Promoter probe for CSF2: 
AAGTTCTCTGGAGGATGTGGCTGC/CCATCTCAGCAGCAGTGTCTCTAC. Control 
probe for CSF2: TGGGGGATGCTGGGGTTATGTA/
TAGCCCCCAGAAGACACCAGGAG.
Phosphatidylinositol-Specific Phospholipase C Protein (PI-PLC) treatment
THP1 monocytes were resuspended in PBS at 2 million cells/ml, and incubated with 1u/ml 
PI-PLC (Invitrogen #P-6466) at 37°C for 1 hr. Monocytes were then washed with PBS once 
and resuspended in MEGM medium for coculture experiments.
Animal experiments
All research involving animals complied with protocols approved by the MIT Committee on 
Animal Care. The number of cells and the time for tumor growth are indicated in the figure 
legends. To measure tumor-initiating cell/CSC frequency (Fig. 2a,g, 4h, 6e; Supplementary 
Fig. 2d,f), serial dilutions of cancer cell suspensions in 25 μl of a 1:1 MEGM and Matrigel 
(BD Biosciences) mixture were injected into the 4th mammary fat pads of 2–3 months old 
Lu et al. Page 13
Nat Cell Biol. Author manuscript; available in PMC 2015 January 16.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
female NOD-SCID mice. CSC frequencies of the samples were determined using the ELDA 
webtool65. In TAMs+CSCs co-injection experiments (including the CSCs only control 
groups; Fig. 4a–f & 7d), the amount of Matrigel was reduced by 6-fold to minimize any 
effects of growth factors from the Matrigel. Thus, the cells were suspended in 10 μl of a 4:1 
MEGM and Matrigel mixture and injected into the 4th mammary fat pads of 2-month old 
female Nude mice. For the MMTV-PyMT tumor cell transplantation experiment (Fig. 4i,j; 
Supplementary Fig. 4 d–j), naturally arising MMTV-PyMT tumors from 10–14 week old 
females were harvested (with their lungs being checked for visible macrometastases to 
gauge the metastatic capabilities of the tumor cells). The tumor cells were dissociated into 
single-cell suspension, subjected to negative selection by CD45, CD31 and Ter-119 
microbeads (Miltenyi) and then sorted for CD90 expression. Separate MMTV-PyMT tumors 
were dissociated for the isolation of TAMs. 3x105 tumor cells were injected with or without 
1.5x105 TAMs in a volume of 10 μl including 2 μl Matrigel into the 4th mammary fat pads 
of 2-month old female wildtype Fvb mice. Tumors and lungs were harvested after two 
months. Tumor weight was measured after draining of fluid in the cysts-containing tumors. 
Investigator was not blinded to the group allocation for the assessment of outcome. Mice 
were randomly allocated to each group by an independent person; however, no particular 
method of randomization was used. No statistical method was used to predetermine sample 
size.
Patient samples
The tissues used in this study were collected under a University of Pittsburgh Internal 
Review Board (UPCI 04-162). All patients were consented prior to surgery or any other 
clinically indicated procedure. All specimens are de-identified by an honest broker system 
and distributed for research. Tissues used for immunohistology were processed within 2 
hours of surgery.
Immunohistostaining
Mouse tumors—Formalin-fixed paraffin-embedded xenograft tumor tissue slides were 
stained with primary antibodies mouse anti-α-SMA (Sigma), rat anti-F4/80 (Invitrogen, 
MF48000), rabbit anti-PLCγ1 (pY783)(Abcam, #ab53125), rabbit anti-cleaved caspase 3 
(CST #9664) and mouse anti-Ki67 (BD Biosciences #550609), and the secondary antibodies 
used are goat anti-mouse Alexa594, goat anti-rat Alexa488, and donkey anti-rabbit Alexa 
555 (Supplementary Table 6). Nuclear staining was performed with DAPI (Invitrogen). 
Slides were mounted in Prolong Gold anti-fade reagent (Invitrogen). Immunofluorescent 
staining was observed and photographed using a Nikon Eclipse E800 upright fluorescence 
microscope.
Patient tumor tissues—All tissues BrCA022T, BrCA032T, BrCA041T (invasive ductal 
carcinomas, ER+/PR+) and BrCA042T (invasive ductal carcinoma, ER−/PR−) were 
formalin-fixed and paraffin-embedded. Antigen retrieval of tissue sections were performed 
at 125°C for 20 min in pH 6.0-EDTA buffer (Dako), washed and blocked with blocking 
solution (PBS, 5% goat serum, 0.05% Tween 20) to reduce nonspecific antibody binding. 
All wash steps were performed with DAKO wash buffer. Immunofluorescence staining was 
performed using the following primary antibodies overnight at 4°C: monoclonal rabbit anti-
Lu et al. Page 14
Nat Cell Biol. Author manuscript; available in PMC 2015 January 16.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
human CD90 (Abcam, Cat. No. ab133350), mouse anti-human CD68 (Dako Cat. No. 
M0876). Negative Control primary antibodies were purchased from Dako (N1698 and 
N1699). After washing, biotinylated secondary goat anti-rabbit biotin (Dako Cat. 
No.E0432), goat anti-mouse Alexa488 antibody (CD90/CD68 double staining, Invitrogen 
Cat. No. A11001), or goat anti-mouse Cy5 antibody (CD90/CD68/CTK triple staining; 
Abcam Cat. No. ab97037) were applied for 1 hour at room temperature, followed by 
incubation with streptavidin-Cy3 (Sigma, Cat. No. 6402) for 30 minutes at room 
temperature. For triple staining mouse anti-CTK-FITC [AE1/AE3] (eBioscience, Cat. No. 
53-9003-80) was incubated for 1 hr at room temperature. For detailed information on 
antibodies used see Supplementary Table 6. Final nuclear staining was performed with 
DAPI (Invitrogen, Cat. No. D1306). Slides were mounted in Prolong Gold anti-fade reagent 
(Invitrogen, Cat. No. P36934). Immunofluorescent staining was observed and photographed 
using a Nikon 90i motorized upright epi-fluorescence microscope using a 20X objective. 
Whole sections were photographed as a composite of individual “tiles” captured and joined 
using the NIS-Elements software. Individual CD90+/CD68+ cellular doublets were 
identified from the 20X whole section tiled images. Confocal images of the doublets were 
obtained using a Olympus Fluoview 1000 microscope (version 2.16 software) and a Plan 
Apo N 60X 1.42 N.A. objective, 4x zoom, and 0.45 μm sections (number varied depending 
on cells imaged: 13–17). Stacks were processed using MetaMorph (version 7.7) and 
autocontrast was applied consistently to all wavelengths.
Statistical analysis
Data are presented as mean ± SEM. Student’s t test (unpaired) was used to compare two 
groups (p< 0.05 being considered significant). Holm-Sidak’s multiple comparisons test was 
performed when one-way ANOVA was used to compare between more than two groups. 
Sample sizes were indicated in each corresponding figure legends.
Proteomic analysis of membrane pellet samples
SILAC media for HMLE-vector and HMLE-Twist cells were made based on MCDB-17066. 
For the amino acid labeling, either normal L-lysine and L-arginine or heavy-
labeled 13C6-15N2 lysine and 13C6-15N4 arginine were supplemented at concentrations of 
40 mg/L and 120 mg/L, respectively. Labeled cells were harvested after 8 cell doublings.
Membrane protein fractionation—Membrane proteins isolation was described in 
Supplementary Fig. 1b,c. The buffers used are as follows. Lysis buffer: 10 mM Tris, pH 7.5, 
5 mM MgCl2, 0.5 mM PMSF, add 0.5% PMSF and 1% protease inhibitors (Sigma) fresh 
before use. Sucrose buffer: 10 mM Tris, pH 7.5, 1.25 M Sucrose (MW 342.3). Membrane 
proteins were pelleted with ultraclear tube (Beckman #344057) in Beckman ultracentrifuge 
(model# L8-M) with rotor SW50.1.
Solubilization, digestion, and peptide fractionation by off-gel electrophoresis
—1 mg membrane protein pellets were solubilized in urea and disulfide bonds were reduced 
and alkylated, then proteins were deglycosylated with PNGaseF and digested with Lys-C, 
and trypsin. Solutions that began cloudy upon initial reconstitution were clear after 
overnight digestion. ~50 μg samples of peptide digest were separated by off-gel 
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electrophoresis (OGE) according to isoelectric point into 11 fractions using an Agilent 3100 
OFFGEL Fractionator (Agilent Technologies, Wilmington, DE) and 13 cm Immobiline 
Drystrips pH 3–10 (GE Healthcare BioSciences AB, Uppsala, Sweden). Experimental 
details have been previously described67.
Mass Spectrometry—Peptide off-gel electrophoresis fractions were analyzed with an 
automated nano LC-MS/MS system, consisting of an Agilent 1100 nano-LC system (Agilent 
Technologies, Wilmington, DE) coupled to either an LTQ-Orbitrap or an LTQ Orbitrap XL 
Fourier transform mass spectrometer (Thermo Fisher Scientific, San Jose, CA) equipped 
with a nanoflow ionization source (James A. Hill Instrument Services, Arlington, MA). 
Peptides were eluted from a 10 cm column (Picofrit 75 um ID, New Objectives) packed in-
house with ReproSil-Pur C18-AQ 3 μm reversed phase resin (Dr. Maisch, Ammerbuch 
Germany) using either a 120 or 133 min. gradient at a flow rate of 200 nl/min to yield ~20 s 
peak widths as previously described75. Data-dependent LC-MS/MS spectra were acquired in 
~3 s cycles; each cycle was of the following form: one full Orbitrap MS scan at 60,000 
resolution followed by 8 MS/MS scans in the ion trap on the most abundant precursor ions 
using an isolation width of 3 m/z. Dynamic exclusion was enabled with a mass width of +/− 
25 ppm, a repeat count of 1 and an exclusion duration of 45 sec. Charge-state screening was 
enabled along with monoisotopic precursor selection and non-peptide monoisotopic 
recognition to prevent triggering of MS/MS on precursor ions with unassigned charge or a 
charge state of 1. Normalized collision energy was set to 30 with an activation Q of 0.25 and 
activation time of 30 ms. 2 biological replicates were performed.
Protein identification and quantitation—All MS data was interpreted using the 
Spectrum Mill software package v4.1 beta (co-developed by us with Agilent Technologies, 
Santa Clara, CA). Similar MS/MS spectra acquired on the same precursor m/z within +/− 45 
sec were merged, MS/MS spectra with precursor charge >4 and poor quality MS/MS 
spectra, which failed the quality filter by not having a sequence tag length > 0 (i.e., 
minimum of two masses separated by the in-chain mass of an amino acid) were excluded 
from searching. MS/MS spectra were searched against a UniProt database containing 78,369 
human sequences (including isoforms and excluding fragments) downloaded from the 
UniProt web site on June 30, 2010, along with 73 common laboratory contaminant proteins 
appended. Search parameters included: ESI linear ion-trap scoring parameters, trypsin 
enzyme specificity with cleavage at K-P or R-P allowed, a maximum of 4 missed cleavages, 
35% minimum matched peak intensity, +/− 20 ppm precursor mass tolerance, +/−0.7 Da 
product mass tolerance, and fixed/mix modifications that included carbamidomethylation of 
cysteines and either unlabeled Arg, Lys or SILAC labeled Arg-10, Lys-8. Allowed variable 
modifications were oxidized methionine, deamidation of asparagine, pyro-glutamic acid 
modification at N-terminal glutamine, and pyro-carbamidomethyl modification at N-
terminal cysteine with a precursor MH+ shift range of −18 to 64 Da.
Identities interpreted for individual spectra were automatically designated as confidently 
assigned using the Spectrum Mill autovalidation module to apply target-decoy based false-
discovery rate (FDR) scoring threshold criteria via a two-step auto threshold strategy at the 
spectral and protein levels. First, peptide mode was set to allow automatic variable range 
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precursor mass filtering with score thresholds optimized to yield at spectral level FDR of 
1.6% for each precursor charge state in each LC-MS/MS run. Second, protein mode was 
applied to further filter all the peptide-level validated spectra combined from the 22 LC-
MS/MS runs from both replicates of an experiment using a minimum protein score of 20 and 
a maximum protein-level FDR of zero. Since the maximum peptide score is 25, the protein 
level step filters the results so that each identified protein is comprised of multiple peptides 
unless a single excellent scoring peptide was the sole match. The above criteria yielded 
target-decoy based FDR estimates for each sample replicate of 0.9 to 1.0% at the peptide-
spectrum match level and 1.3 to 1.5 % at the distinct peptide level.
For scores calculated at the protein level and reporting of identified proteins, redundancy is 
addressed as follows. The protein score is the sum of the scores of distinct peptides. A 
distinct peptide is the single highest scoring instance of a peptide identified by an MS/MS 
spectrum. MS/MS spectra for a particular peptide may have been recorded multiple times, 
(i.e. both heavy and light SILAC labels, different precursor charge states, isolated from 
adjacent OGE fractions, modified by deamidation at Asn or oxidation of Met) but are still 
counted as a single distinct peptide. When a peptide sequence >8 residues long is contained 
in multiple protein entries in the sequence database, the proteins are grouped together and 
the highest scoring one and its accession number are reported. In some cases when the 
protein sequences are grouped in this manner there are distinct peptides which uniquely 
represent a lower scoring member of the group (isoforms, family members). Each of these 
instances spawns a subgroup and multiple subgroups are reported and counted towards the 
total number of proteins with each given related protein.subgroup numbers (e.g., the ephrin 
receptor tyrosine kinase family shares sufficient sequence homology that the observed 
shared and distinct peptides resulted in one protein group with 4 subgroups corresponding to 
EPHA2, EPHA4, EPHB2, and EPHB4 and are listed as subgroup members 214.1 thru 214.4 
in Supplementary Table 1). GO annotations were then used to categorize all of the identified 
protein subgroups as being plasma membrane associated, extra cellular matrix derived, 
and/or tyrosine kinases. EphA4 is complicated by the fact that there is over 50% sequence 
identity among the Ephrin family members with distinct peptides detected for EphA2, A4, 
B2, B4. In each replicate a single distinct A4 tryptic peptide was observed, different ones 
each time, and both showed > 20-fold expression increase (data not shown). The peptides 
that are shared amongst family members and those distinct to the other three isoforms do not 
show significant expression change. The marginal distinct A4 evidence resulted from the 
median ratio of all its constituent peptides being below the significant change threshold in 
each replicate (Fig. 1a, Supplementary Table 1).
SILAC relative abundance ratios of proteins were determined using extracted ion 
chromatograms (XIC’s) for each sequenced peptide’s light and heavy labeled precursor ion 
pair in the intervening high resolution FT-MS scans of the LC-MS/MS runs as previously 
described75. Each individual protein’s SILAC ratio was calculated as the median of all 
SILAC precursor ion ratios corresponding to MS/MS spectra confidently assigned to 
peptides from that protein. Proteins were considered quantifiable if they were observed in 
each of 2 replicate experiments with at least 2 SILAC ratios measured in each experiment. 
Ratios for common laboratory contaminant proteins were filtered out of each dataset. 
Because two biological replicate experiments were performed with a light/heavy label-swap 
Lu et al. Page 17
Nat Cell Biol. Author manuscript; available in PMC 2015 January 16.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
between experiments the contaminants were easily recognizable not only by identity but also 
by extreme quantitation ratios with nearly all signals in the light channel. To assign 
regulated proteins (Fig. 1a, Supplementary Table 1). We used the Limma package in the R 
environment to calculate moderated T-test p-values corrected by the Benjamini Hochberg 
method, as described previously17. In order to perform the moderated T-test, the protein 
SILAC ratios were standardized (distributions centered at zero and replicate 1 vs 2 
diagonalized). Each log 2 protein ratio in a replicate experiment was standardized by 
subtracting the median and dividing by the standard deviation of all log2 protein ratios in 
that replicate.
Repeatability of experiments
Representative images were shown in Fig. 1–4,6,7; Suppl. fig. 1–4, 6. The experiments have 
been repeated as follows:
Main Fig: (1b,d) 3 repeats, (2b,c) 5 repeats. (3a,b) see fig., (3c) 3 repeats, (3e) 5 patient 
tumors, (3i) 25 tumor biopsies. 4d, 3 repeats, (6a–c,f,7e) 3 repeats. (6h,7c,f) 2 repeats. 
Suppl. Fig: (S1c) 3 repeats. (S2e,h) 4 repeats. (S2g) 2 repeats. (S3a,c,d,4c) 5 patient tumors. 
(S3b) 25 tumor biopsies. (S4e–g,i,) 2 repeats, (S6a,f,g) 2 repeats. (S6c) 3 repeats.
Data Deposition
The original mass spectra may be downloaded from MassIVE (http://massive.ucsd.edu) 
using the identifier: MSV000078799. The data is accessible at ftp://
MSV000078799:a@massive.ucsd.edu.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Quantitative proteomic profiling identified EMT-induced membrane protein changes 
in HMECs
(a) Expression ratios of proteins detected in the mesenchymal HMLE-Twist cells over the 
epithelial HMLE-vector cells plotted for two biological replicate experiments. Ratios 
highlighted in red were found to be significantly differentially expressed (p<0.05) after 
standardizing and applying a moderated T-test corrected by the Benjamini Hochberg 
method17. Gene names were labeled for known EMT marker proteins and candidates that 
were followed up in this study. (b) The HMLE, HMLE-Twist and HMLE-Snail cells were 
stained with anti-CD90 and anti-CD24 antibodies and analyzed by flow cytometry. The 
percentage of the CD90hiCD24− population was shown on each plot. (c,d) The cells were 
FACS sorted based on CD90 and CD24 levels and seeded into 3D mammosphere medium. 
The numbers of mammospheres were plotted (c), and representative pictures of 
mammospheres formed by the indicated cell populations are shown (d). n= 3 independent 
experiments. *** p<0.001; **** p<0.0001 (Student’s t-test). Source data provided in 
Supplementary Table 7.
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Figure 2. Enrichment of CD90 protein on the cell surface of EMT/stem-like cells
(a) HMLE-Ras cells were FACS-separated and then injected orthotopically into NOD-SCID 
mice in a limiting dilution assay. The tumor initiation rates are shown, with the estimated 
CSC-frequency displayed for the bulk and the CD90hiCD24− populations. N.D., not 
determined. (b,c) H&E staining comparing xenograft tumors (b) and lungs (c) of mice 
receiving injections from the bulk and CD90hiCD24− HMLER cells. Black arrows (c) 
indicate macro-metastasis from the CD90hiCD24− tumors. The numbers of macro-
metastases per lung are shown in (d; n=5 mice). (e,f) Correlation of CD90 level in patient 
tumors with relapse-free survival. High CD90 expression (red line) was significantly 
correlated with poor prognosis in ER− (H; n=457, p=1.7×10−5) and ER+ (I; n=1413, 
p=0.013) breast cancer patients. The plots were generated using http://kmplot.com (probe: 
213869_x_at).58 (g) HMLER90hi cells with or without shCD90 were injected orthotopically 
into mice and the tumor size were measured weekly during a course of 50 days. n=10 mice. 
Knockdown of CD90 by the shRNA was confirmed by flow cytometry analysis 
(Supplementary Fig. 2h). All error bars shown indicate S.E.M. * p<0.05; ** p<0.01; *** 
p<0.001 (Student’s t-test).
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Figure 3. CD90 serves as an anchor for the adherence of monocytes and macrophages
(a) THP1-RFP monocytes were cocultured with monolayer HMLER-GFP cells. Monocytes 
that did not adhere to the HMLER monolayer were washed away after 1 hr and the adherent 
cells were imaged and then quantified by flow cytometry based on GFP and RFP expression. 
Representative images (a) and flow cytometry profiles (b) are shown. The ratios of the 
adhered monocytes to the HMLER cells were calculated from the flow-cytometry 
quantitation in panel (b); data presented as mean ± s.e.m. (c) Immunofluorescence (IF) 
staining of CD90 (red) and F4/80 (green) in HMLER90hi xenograft tumors. The dotted lines 
delineate the border between the tumor cells and stroma. Scale bar: 0.1mm. (d) Quantitation 
of CD90 signal and F4/80 signal intensity from tumor edge to center. n=5 tumors. (e) 60x 
confocal images of primary patient breast tumor sections co-stained for CD90+ CSCs (red) 
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and CD68+ TAMs (green) showed juxtaposed CSC-TAM pairs. (f,g) Numbers of CD90high 
CSCs (f) or CD90−CTK+ non-CSCs with or without adjacent TAMs were counted from 3–6 
representative fields of 20x or 25x images (n=4 patients). The percentages shown indicate 
the proportion of cancer cells with adjacent TAMs. Error bars indicate S.E.M. Source data 
for g provided in Supplementary Table 7. (h) The numbers of CD90+CTK+, CD90+CTK−, 
CD90−CTK+ cancer cells and CD68+ macrophages in the same microscopic field (0.6 mm2) 
were quantified from 25 core biopsy sections. The number of CD90+CTK− CSCs correlates 
with the number of CD68+ TAMs. The CD90+ endothelial cells and fibroblasts were 
excluded from the cancer cell counts based on morphology. (i) Typical images showing 
infiltration of CD68+ TAMs into the CD90+ CSC-rich areas but not the CD90−CTK+ cancer 
cell islands.
Lu et al. Page 25
Nat Cell Biol. Author manuscript; available in PMC 2015 January 16.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4. Macrophages enhance tumor initiation by the CD90hi CSC-like cells
(a) CD90hi CSCs were mixed with PBS- or clodronate- liposomes and orthotopically 
implanted into Nude mice (n=10 per group). Data were pooled from 2 independent 
experiments, each assessing 5 mice per group. The tumors were harvested 50 days later and 
weighed. (b) 105 HMLER90hi cells were injected either alone or co-mixed with 5×104 
human monocytes (huMono) or mice TAMs, into the mammary fat pads of female Nude 
mice. n=9,12,12 mice (left to right). Reduced amount of Matrigel was used for the injection 
mix. The tumor weight was measured after 5 weeks. Data from 3 independent experiments 
were pooled and plotted. (c,d) Naturally arising MMTV-PyMT tumors were dissociated and 
tumor cells were sorted based on CD90 expression, whereas TAMs were isolated by F4/80 
expression. 3x105 CD90+ or CD90− tumor cells were orthotopically transplanted into 
syngeneic wildtype Fvb mice with or without comixed 1.5x105 TAMs. (c) The numbers of 
lung macro-metastases from tumor-bearing mice were quantified and normalized to primary 
tumor weight (per gram), shown as metastatic index. Data were pooled from 3 independent 
experiments. n=13,14,14,14 mice from left to right (15 mice were injected for each group, 
but not all mice developed tumors; see Supplementary Fig. 4d). (d) H&E staining of the 
lungs of tumor-bearing mice. (e–g) CD90hi CSCs were injected alone (e) or with admixed 
Lu et al. Page 26
Nat Cell Biol. Author manuscript; available in PMC 2015 January 16.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
TAMs (f) at limiting dilution orthotopically (n=10 mice per group). Data were pooled from 
2 independent experiments, each assessing 5 mice per group. Tumor incidence was 
determined by weekly palpation, and tumors were harvested and weighed at 50 days post 
injection (g). (h) CD90lo non-CSCs were injected alone or with admixed TAMs 
orthotopically but no tumor formed. Data were pooled from 2 independent experiments, 
each assessing 5 mice per group. (i,j) HMLER90hi cells injected alone or together with 
TAMs were allowed to grow in the mammary fat pads of NOD-SCID mice for 3 weeks; the 
tumor cells were then harvested and seeded for tumorsphere forming assay (i; presents data 
from 4 technical replicates) or injected as secondary tumor transplants into recipient NOD-
SCID mice (j) to measure tumor-initiating capability. Data shown are from one experiment 
out of two biological replicates; source data provided in Supplementary Table 7 (i,j). Error 
bars indicate S.E.M. * p<0.05; *** p<0.001; *** p<0.0001 (Student’s t-test for a,b,g and 
one way ANOVA for c).
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Figure 5. Monocytes induce cytokine production in the CSCs upon contact
(a) Induction of cytokine mRNA in the HMLER90hi or HMLER90lo cells when cocultured 
with the THP1 monocytes for indicated time. HMLER90hi-memb, an indirect coculture 
where the two cell types were separated by a cell-impermeable insert. Data from one 
experiment was shown as averages of three technical replicates. Two biological replicates 
were performed. (b) ELISA measurement of the secreted cytokines from the coculture. n=3 
independent experiments. Error bars indicate S.E.M. Source data shown in Supplementary 
Table 7. (c) Cytokine mRNA fold-change stimulated by THP1 monocytes (relative to 
corresponding no monocytes control) in the epithelial HMLE, mesenchymal HMLE-Twist, 
HMLE-Slug CD90hiCD24−, HMLER90hi cells and HMLER90hi with shCD90. (d,e) 
Cytokine mRNA fold-changes in the HMLE-derived cells stimulated by mouse primary 
macrophages (d) or human blood monocytes (e). The HMLER90hi-IκBmut cells lacking 
NF-κB activation showed no cytokine production. Typical data shown from one experiment 
out of 3 (a,b) and 2 (c–e) biological replicates, only technical replicate data are plotted. 
Source data provided in Supplementary Table 7.
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Figure 6. EphA4 mediates signal transduction in the CSCs upon stimulation by the monocytes
(a) Phospho- and total-protein levels of EphA4 as well as downstream proteins PLCγ1, 
PKCδ and Src in the two cocultured cell types were detected by western blot. GFP and RFP 
were only detected in the corresponding cell populations with minimum cross-
contamination. Numbers above each lane indicate minutes of coculture. Phospho-EphA4 
was detected with an antibody that non-discriminatively recognizes the phosphorylated 
forms of EphA3, 4 and 5. (b) Indirect coculture (membrane) with monocytes did not lead to 
activation of EphA4 and downstream proteins in the CSCs. (c) Treatment of HMLER90hi 
cells with an EphA4-specific inhibitor peptide KYL prior to and during coculture with 
monocytes resulted in decreased phosphorylation. A scrambled peptide (KYL-P7A) served 
as control. The largely diminished phosphorylation level with KYL treatment indicated that 
the signals detected by the phospho-EphA3/4/5 antibody were mostly from activated 
EphA4. The numbers below each panel are the intensities of the bands quantified using Fiji 
software and normalized to GFP (bottom panel) of the corresponding samples. (d) Cytokine 
secretion from coculture treated with KYL or KYL-P7A was measured by ELISA. 
Technical replicate data are plotted. Source data provided in Supplementary Table 7. (e) 
1x105 HMLER90hi parental cells or HMLER90hi with sh-Luciferase or sh-EphA4 were 
orthotopically implanted into NOD-SCID mice. n=8 mice (Data were pooled from 2 
independent experiments, each assessing 4 mice per group). The tumors were harvested 40 
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days after implantation and weighed. **** p<0.0001 (One way ANOVA). Error bars 
indicate S.D. (f) Western blots measuring levels of knockdown with 2 pairs of shRNA each 
for PLCγ1 and PKCδ in the HMLER90hi cells. (g) Cytokine mRNA induction in the 
HMLER90hi cells with PLCγ1 and PKCδ knockdown. Technical replicate data are 
presented as mRNA fold-changes in the HMLER90hi cells upon monocyte coculture. 
Source data provided in Supplementary Table 7. (h) IF staining of xenograft tumors with 
antibodies against phopho-PLCγ1 (Tyr783) and F4/80. White arrowheads point to the 
phospho-PLCγ1+ cells (red) surrounded by F4/80+ TAMs (green). Areas with no TAMs 
showed no phopho-PLCγ1 signals (bottom panel).
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Figure 7. NF-κB activation is required for monocytes-stimulated cytokine production in the 
CSCs
(a) The mRNA levels and (b) secreted cytokine concentrations of IL-6, IL-8 and GM-CSF 
in the HMLER90hi parental cells and the NF-κB super-repressor-expressing cells 
(HMLER90hi-IκB-mut) with or without monocyte coculture were measured by Q-PCR and 
ELISA. n=3 biological replicates (with 3 technical repeats each). Source data provided in 
Supplementary Table 7. Error bars indicate S.E.M. (c) The HMLER90hi cells, alone or in 
coculture with monocytes (the latter was removed prior to cell harvest), were lysed and 
fractionated to obtain the cytosolic and nucleus extracts. NF-κB subunits were 
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immunoblotted to show the nuclear translocation. GAPDH and SV40-LgT served as 
cytosolic and nucleus protein controls. (d) The IκBα mutant-expressing HMLER90hi cells 
(CSC-Ikb-mut) were injected, either alone (□) or co-mixed with human monocytes 
(huMono, □) or with mice TAMs (□), into the mammary fat pads of female Nude mice. 
Tumor weight was measured after 7 weeks and data from 2 independent experiments were 
pooled. n=8,12,12,10,10 mice (left to right). Error bars indicate S.E.M. (e) IF staining of 
tumors from HMLER90hi CSCs alone or CSCs+TAMs with antibodies against cleaved 
caspase 3 (apoptosis marker) and Ki67 (proliferation marker). (f) The endogenous Twist 
proteins were immunoprecipitated from the HMLER90hi cells, and then immunoblotted for 
NF-κB subunit p50 to demonstrate complex formation. (g) Binding of both Twist and NF-
κB at the promoters of IL6, IL8 and CSF2 (GM-CSF) in the HMLER90hi cells alone or in 
coculture was measured by ChIP-PCR. Data was represented as fold-enrichment of binding 
to the specific segments relative to background average. The positions of probes were 
illustrated below the graphs. Data plotted are technical replicates. Source data from two 
biological replicates are provided in Supplementary Table 7. (h) A depiction of the signaling 
transduction pathway in a CSC when stimulated by a monocyte/macrophage.
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